Drugs & Therapy Perspectives

, Volume 23, Issue 7, pp 5–8 | Cite as

Lisdexamfetamine: a guide to its use in attention-deficit hyperactivity disorder in children

Drug and Profile Report


  1. 1.
    Blick SKA, Keating GM. Lisdexamfetamine. Pediatr Drugs 2007; 9(2); 129–35CrossRefGoogle Scholar
  2. 2.
    Vyvanse™ (lisdexamfetamine dimesylate); US prescribing information. Wayne (PA): Shire US Inc., 2007 FebGoogle Scholar
  3. 3.
    Buitelaar JK, Montgomery SA, van Zwieten-Boot BJ. Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention. Eur Neuropsychopharmacol 2003 Aug; 13(4): 297–304PubMedCrossRefGoogle Scholar
  4. 4.
    Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder Committee on Quality Improvement. Pediatrics 2001; 108(4): 1033–44CrossRefGoogle Scholar
  5. 5.
    Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007 Mar; 29(3): 1–14CrossRefGoogle Scholar
  6. 6.
    Krishnan S, Moncrief S. An evaluation of the CYP450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos 2007; 35: 180–4PubMedCrossRefGoogle Scholar
  7. 7.
    Connor DF, Steingard RJ. New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential. CNS Drugs 2004; 18(14): 1011–30Google Scholar
  8. 8.
    de La Torre R, Farré M, Navarro M, et al. Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. Clin Pharmacokinet 2004; 43(3): 157–85PubMedCrossRefGoogle Scholar
  9. 9.
    Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998 Jul; 94(1): 127–52PubMedCrossRefGoogle Scholar
  10. 10.
    Jasinski D, Krishnan S. Pharmacokinetics of oral lisdexamfetamine dimesylate (LDZ; NRP104) vs d-amphetamine in healthy adults with a history of stimulant abuse [poster]. 19th Annual US Psychiatric and Mental Health Congress; 2006 Nov 15–19; New Orleans (LA)Google Scholar
  11. 11.
    Jasinski D, Krishnan S. A double-blind, randomized, placebo- and active-controlled, 6-period crossover study to evaluate the likability, safety, and abuse potential of lisdexamfetamine dimesylate (LDX) in adult stimulant abusers [poster]. 19th Annual US Psychiatric and Mental Health Congress; 2006 Nov 15–19; New Orleans (LA) Google Scholar
  12. 12.
    Biederman J, Boellner S, Childress A, et al. Improvements in symptoms of ADHD in school-aged children with lisdexamfetamine (SPD489/NPR104) and extended-release mixed amphetamine salts versus placebo [abstract no. NR631 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20–25; Toronto (ON)Google Scholar
  13. 13.
    Data on file, Shire Development Inc., 2007 Feb 15Google Scholar
  14. 14.
    Childress AC, Krishnan S, McGough JJ, et al. Interim analysis of a long-term, open-label, single-arm study of lisdexamfetamine (LDX), an amphetamine prodrug, in children with ADHD [poster]. 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2006 Oct 24–29; San Diego (CA)Google Scholar

Copyright information

© Adis Data Information BV 2007

Personalised recommendations